Serzone withdrawal sought by Public Citizen
Executive Summary
Public Citizen sues FDA to force the withdrawal of Bristol-Myers Squibb's antidepressant Serzone (nefazodone). The 1suit, filed in D.C. federal court March 15, cites a "mounting number of deaths and serious injuries from liver failure." The lawsuit follows a March 5, 2003 citizen petition from Public Citizen - supplemented in October - asking FDA to withdraw the product (2"The Pink Sheet" March 10, 2003, p. 17)...
You may also be interested in...
Public Citizen Wants Serzone Pulled; No “Unique” Benefit To Offset Risk
Bristol-Myers Squibb's Serzone offers "no unique therapeutic benefit" to justify continued marketing in light of liver toxicity concerns, Public Citizen maintains in a March 6 petition to FDA
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.